Saturday 17 October 2026
Export GANX’s income statement to Excel — free account
Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
1.26
0.07
−5.26%
Follow GANX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.81 | 4.26 | 6.22 | 2.11 | |
Current Ratio |
4.36 | 4.69 | 6.63 | 2.52 | |
Net Debt/EBITDA |
2.74 | 3.03 | 4.61 | 1.76 | |
Debt/Assets |
2.23% | 1.99% | 1.76% | 3.87% | |
Debt/Equity |
0.03 | 0.03 | 0.02 | 0.07 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 0.84 | 1.02 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.11) | (0.14) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.11) | (0.14) | (0.14) | |
Cash per Share |
0.31 | 0.39 | 0.63 | 0.25 | |
Shareholders Equity per Share |
0.26 | 0.33 | 0.56 | 0.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.26 | 0.33 | 0.56 | 0.17 | |
Free Cash Flow |
(4.68) | (4.73) | (4.62) | (4.93) | |
Working Capital |
11.54 | 14.34 | 18.88 | 6.35 | |
Net Current Asset Value |
10.84 | 13.49 | 17.98 | 5.46 | |
| Other line items | |||||
Average Payables |
1.97 | 1.83 | 0.89 | 1.34 | |
Average Assets |
12.63 | 15.18 | 17.47 | 12.67 | |
Average Common Equity |
7.49 | 9.89 | 12.95 | 7.41 |
Columns are period end dates